News for Lexicon Pharmaceuticals, Inc. (LXRX)

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) was one of the stocks that was covered in that article. Wall Street analysts believe LXRX has a 285% upside potential over the next 12 months. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company with a pioneering approach […]

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) was one of the stocks that was covered in that article.

Lexicon Pharmaceuticals (LXRX) recently shared the design of its "SONATA-HCM" study, focusing on the effects of sotagliflozin in patients suffering from both ob

Release Date: May 13, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Lexicon Pharmaceu

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NLXRX.OQ - Lexicon Pharmaceuticals IncQ1 2025 Lexicon Pharmaceuticals Inc Earnings CallMay 13,

Lexicon Pharmaceuticals strikes a $75 million licensing deal with Novo Nordisk, paving the way for innovation in diabetic treatment. Phase 3 trials for

The following slide deck was published by Lexicon Pharmaceuticals, Inc.

Revenue: $1.3 million, below the estimated $1.41 million.Earnings Per Share (EPS): Reported EPS of -$0.07, outperforming the estimated EPS of -$0.10.Net Loss:

Lexicon Pharmaceuticals (LXRX) reported its first-quarter revenue at $1.26 million, surpassing the market expectation of $1.18 million. The company achieved sig

Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling stu

As of April 25, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading d...

U.S. stock futures fell on Monday after three consecutive days of decline on Friday. Futures of benchmark indices were lower in premarket.

Lexicon Pharmaceuticals (LXRX) has finalized an exclusive license agreement with Novo Nordisk for the development and commercialization of LX9851, a groundbreak

S&P futures: down 4 points. Nasdaq futures: down 49 points.The S&P 500 futures have fallen by 4 points, the Nasdaq 100 futures by 49 points, and the Dow Jones I

U.S. stocks traded lower this morning, with the Nasdaq Composite falling around 100 points on Friday. Following the market opening Friday, the Dow traded down ...

Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-ter

THE WOODLANDS, Texas, March 07, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. ( LXRX) today announced that Company management will participate in a f

Cash Equivalents and Short-term Investments: $238 million as of December 31, 2024, compared to $170 million as of December 30, 2023.Revenue: $26.6 million in Q

The following slide deck was published by Lexicon Pharmaceuticals, Inc.